{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T19:11:30Z","timestamp":1790709090618,"version":"4.1.0"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"S2","license":[{"start":{"date-parts":[[2008,6,1]],"date-time":"2008-06-01T00:00:00Z","timestamp":1212278400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2008,6,1]],"date-time":"2008-06-01T00:00:00Z","timestamp":1212278400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2008,6,1]]},"DOI":"10.1038\/bmt.2008.69","type":"journal-article","created":{"date-parts":[[2008,6,11]],"date-time":"2008-06-11T04:09:50Z","timestamp":1213157390000},"page":"S118-S127","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":86,"title":["28 years of high-dose therapy and SCT for neuroblastoma in Europe: lessons from more than 4000 procedures"],"prefix":"10.1038","volume":"41","author":[{"given":"R","family":"Ladenstein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U","family":"P\u00f6tschger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O","family":"Hartman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A D J","family":"Pearson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Klingebiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V","family":"Castel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I","family":"Yaniv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Demirer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Dini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the EBMT Paediatric Working Party","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2008,6,11]]},"reference":[{"key":"BFbmt200869_CR1","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1056\/NEJM199910143411601","volume":"341","author":"KK Matthay","year":"1999","unstructured":"Matthay KK, Villablanca JG, Seeger RC, Stram DO, Harris RE, Ramsay NK et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Eng J Med 1999; 341: 1165\u20131173.","journal-title":"N Eng J Med"},{"key":"BFbmt200869_CR2","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S1470-2045(05)70291-6","volume":"6","author":"F Berthold","year":"2005","unstructured":"Berthold F, Boos J, Burdach S, Erttmann R, Henze G, Hermann J et al. Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial. Lancet Oncol 2005; 6: 649\u2013658.","journal-title":"Lancet Oncol"},{"key":"BFbmt200869_CR3","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1002\/pbc.20219","volume":"44","author":"J Pritchard","year":"2005","unstructured":"Pritchard J, Cotterill SJ, Germond SM, Imeson J, de Kraker J, Jones DR . High dose melphalan in the treatment of advanced neuroblastoma: results of a randomised trial (ENSG-1) by the European Neuroblastoma Study Group. Ped Blood Canc 2005; 44: 348\u2013357.","journal-title":"Ped Blood Canc"},{"key":"BFbmt200869_CR4","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1200\/JCO.2003.05.191","volume":"21","author":"B De Bernardi","year":"2003","unstructured":"De Bernardi B, Nicolas B, Boni L, Indolfi P, Carli M, Cordero Di Montezemolo L et al. Disseminated neuroblastoma in children older than one year at diagnosis: comparable results with three consecutive high-dose protocols adopted by the Italian Co-Operative Group for Neuroblastoma. J Clin Oncol 2003; 21: 1592\u20131601.","journal-title":"J Clin Oncol"},{"key":"BFbmt200869_CR5","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1200\/JCO.2003.03.025","volume":"21","author":"IM Ambros","year":"2003","unstructured":"Ambros IM, Benard J, Boavida M, Bown N, Caron H, Combaret V et al. Quality assessment of genetic markers used for therapy stratification. J Clin Oncol 2003; 21: 2077\u20132084.","journal-title":"J Clin Oncol"},{"key":"BFbmt200869_CR6","doi-asserted-by":"crossref","first-page":"6466","DOI":"10.1200\/JCO.2005.05.582","volume":"23","author":"RE George","year":"2005","unstructured":"George RE, London WB, Cohn SL, Maris JM, Kretschmar C, Diller L et al. Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: a Pediatric Oncology Group study. J Clin Oncol 2005; 23: 6466\u20136473.","journal-title":"J Clin Oncol"},{"key":"BFbmt200869_CR7","doi-asserted-by":"crossref","first-page":"6474","DOI":"10.1200\/JCO.2005.05.183","volume":"23","author":"ML Schmidt","year":"2005","unstructured":"Schmidt ML, Lal A, Seeger RC, Maris JM, Shimada H, O'Leary M et al. Favorable prognosis for patients 12\u201318 months of age with stage 4 nonamplified MYCN neuroblastoma: a Children's Cancer Group Study. J Clin Oncol 2005; 23: 6474\u20136480.","journal-title":"J Clin Oncol"},{"key":"BFbmt200869_CR8","doi-asserted-by":"crossref","first-page":"6459","DOI":"10.1200\/JCO.2005.05.571","volume":"23","author":"WB London","year":"2005","unstructured":"London WB, Castleberry RP, Matthay KK, Look AT, Seeger RC, Shimada H et al. Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children's Oncology Group. J Clin Oncol 2005; 23: 6459\u20136465.","journal-title":"J Clin Oncol"},{"key":"BFbmt200869_CR9","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/sj.bmt.1701737","volume":"23","author":"O Hartmann","year":"1999","unstructured":"Hartmann O, Valteau-Couanet D, Vassal G, Lapierre V, Brugieres L, Delgado R et al. Prognostic factors in metastatic neuroblastoma in patients over 1 year of age treated with high-dose chemotherapy and stem cell transplantation: a multivariate analysis in 218 patients treated in a single institution. Bone Marrow Transplant 1999; 23: 789\u2013795.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt200869_CR10","doi-asserted-by":"crossref","first-page":"5693","DOI":"10.1158\/1078-0432.CCR-06-1500","volume":"12","author":"LA Moreau","year":"2006","unstructured":"Moreau LA, McGrady P, London WB, Shimada H, Cohn SL, Maris JM et al. Does MYCN amplification manifested as homogeneously staining regions at diagnosis predict a worse outcome in children with neuroblastoma? A Children's Oncology Group study. Clin Cancer Res 2006; 12: 5693\u20135697.","journal-title":"Clin Cancer Res"},{"key":"BFbmt200869_CR11","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1002\/pbc.20576","volume":"45","author":"JM Maris","year":"2005","unstructured":"Maris JM . How does MYCN amplification make neuroblastomas behave aggressively? Still more questions than answers. Ped Blood Canc 2005; 45: 869\u2013870.","journal-title":"Ped Blood Canc"},{"key":"BFbmt200869_CR12","doi-asserted-by":"crossref","first-page":"e255","DOI":"10.1371\/journal.pone.0000255","volume":"2","author":"RE George","year":"2007","unstructured":"George RE, Attiyeh EF, Li S, Moreau LA, Neuberg D, Li C et al. Genome-wide analysis of neuroblastomas using high-density single nucleotide polymorphism arrays. PLoS ONE 2007; 2: e255.","journal-title":"PLoS ONE"},{"key":"BFbmt200869_CR13","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1002\/1096-911X(20010101)36:1<83::AID-MPO1020>3.0.CO;2-9","volume":"36","author":"R Ladenstein","year":"2001","unstructured":"Ladenstein R, Ambros IM, Potschger U, Amann G, Urban C, Fink FM et al. Prognostic significance of DNA di-tetraploidy in neuroblastoma. Med Ped Oncol 2001; 36: 83\u201392.","journal-title":"Med Ped Oncol"},{"key":"BFbmt200869_CR14","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1056\/NEJMoa052399","volume":"353","author":"EF Attiyeh","year":"2005","unstructured":"Attiyeh EF, London WB, Mosse YP, Wang Q, Winter C, Khazi D et al. Chromosome 1p and 11q deletions and outcome in neuroblastoma. New Eng J Med 2005; 353: 2243\u20132253.","journal-title":"New Eng J Med"},{"key":"BFbmt200869_CR15","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1056\/NEJM199906243402504","volume":"340","author":"N Bown","year":"1999","unstructured":"Bown N, Cotterill S, Lastowska M, O'Neill S, Pearson AD, Plantaz D et al. Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma. New Eng J Med 1999; 340: 1954\u20131961.","journal-title":"New Eng J Med"},{"key":"BFbmt200869_CR16","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1002\/1097-0142(20011101)92:9<2451::AID-CNCR1595>3.0.CO;2-S","volume":"92","author":"H Shimada","year":"2001","unstructured":"Shimada H, Umehara S, Monobe Y, Hachitanda Y, Nakagawa A, Goto S et al. International neuroblastoma pathology classification for prognostic evaluation of patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group. Cancer 2001; 92: 2451\u20132461.","journal-title":"Cancer"},{"key":"BFbmt200869_CR17","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1002\/cncr.11773","volume":"98","author":"M Peuchmaur","year":"2003","unstructured":"Peuchmaur M, d'Amore ES, Joshi VV, Hata J, Roald B, Dehner LP et al. Revision of the International Neuroblastoma Pathology Classification: confirmation of favorable and unfavorable prognostic subsets in ganglioneuroblastoma, nodular. Cancer 2003; 98: 2274\u20132281.","journal-title":"Cancer"},{"key":"BFbmt200869_CR18","first-page":"360","volume":"5","author":"TJ McElwain","year":"1979","unstructured":"McElwain TJ, Hedley DW, Gordon MY, Jarman M, Millar JL, Pritchard J . High dose melphalan and non-cryopreserved autologous bone marrow treatment of malignant melanoma and neuroblastoma. Exp Hematol 1979; 5: 360\u2013371.","journal-title":"Exp Hematol"},{"key":"BFbmt200869_CR19","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/0140-6736(92)93333-I","volume":"340","author":"R Ladenstein","year":"1992","unstructured":"Ladenstein R, Lasset C, Philip T . Treatment duration before bone marrow transplantation in stage IV neuroblastoma. European Bone Marrow Transplant Group Solid Tumour Registry. Lancet 1992; 340: 916\u2013917.","journal-title":"Lancet"},{"key":"BFbmt200869_CR20","first-page":"947","volume":"29A","author":"R Ladenstein","year":"1993","unstructured":"Ladenstein R, Favrot M, Lasset C, Bouffet E, Philip I, Combaret V et al. Indication and limits of megatherapy and bone marrow transplantation in high-risk neuroblastoma: a single centre analysis of prognostic factors. Eur J Cancer 1993; 29A: 947\u2013956.","journal-title":"Eur J Cancer"},{"key":"BFbmt200869_CR21","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1200\/JCO.1998.16.3.953","volume":"16","author":"R Ladenstein","year":"1998","unstructured":"Ladenstein R, Philip T, Lasset C, Hartmann O, Garaventa A, Pinkerton R et al. Multivariate analysis of risk factors in stage 4 neuroblastoma patients over the age of one year treated with megatherapy and stem-cell transplantation: a report from the European Bone Marrow Transplantation Solid Tumor Registry. J Clin Oncol 1998; 16: 953\u2013965.","journal-title":"J Clin Oncol"},{"key":"BFbmt200869_CR22","first-page":"567","volume":"389","author":"TJ Moss","year":"1994","unstructured":"Moss TJ . Sensitive detection of metastatic tumor cells in bone marrow. Progress in clinical and biological research. Prog Clin Biol Res 1994; 389: 567\u2013577.","journal-title":"Prog Clin Biol Res"},{"key":"BFbmt200869_CR23","first-page":"1969","volume":"7","author":"G Mehes","year":"2001","unstructured":"Mehes G, Luegmayr A, Ambros IM, Ladenstein R, Ambros PF . Combined automatic immunological and molecular cytogenetic analysis allows exact identification and quantification of tumor cells in the bone marrow. Clin Cancer Res 2001; 7: 1969\u20131975.","journal-title":"Clin Cancer Res"},{"key":"BFbmt200869_CR24","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1200\/JCO.2000.18.22.3829","volume":"18","author":"LB Faulkner","year":"2000","unstructured":"Faulkner LB, Garaventa A, Paoli A, Tintori V, Tamburini A, Lacitignola L et al. In vivo cytoreduction studies and cell sorting--enhanced tumor-cell detection in high-risk neuroblastoma patients: implications for leukapheresis strategies. J Clin Oncol 2000; 18: 3829\u20133836.","journal-title":"J Clin Oncol"},{"key":"BFbmt200869_CR25","doi-asserted-by":"crossref","first-page":"9503","DOI":"10.1200\/jco.2007.25.18_suppl.9503","volume":"25","author":"SL Cohn","year":"2007","unstructured":"Cohn SL, London WB, Monclaire KK, Matthay K, Ambros PF, Pearson AD . Update on the development of the international neuroblastoma risk group (INRG) classification schema. J Clin Oncol 2007; 2007 ASCO Annual Meeting Proceedings Part I 25(18S): 9503.","journal-title":"J Clin Oncol"},{"key":"BFbmt200869_CR26","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1182\/blood.V78.6.1607.1607","volume":"78","author":"J Graham-Pole","year":"1991","unstructured":"Graham-Pole J, Gee A, Emerson S, Gallo J, Lee C, Luzins J et al. Myeloablative chemoradiotherapy and autologous bone marrow infusions for treatment of neuroblastoma: factors influencing engraftment. Blood 1991; 78: 1607\u20131614.","journal-title":"Blood"},{"key":"BFbmt200869_CR27","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/0959-8049(92)90508-Y","volume":"28A","author":"SJ Gordon","year":"1992","unstructured":"Gordon SJ, Pearson AD, Reid MM, Craft AW . Toxicity of single-day high-dose vincristine, melphalan, etoposide and carboplatin consolidation with autologous bone marrow rescue in advanced neuroblastoma. Eur J Cancer 1992; 28A: 1319\u20131323.","journal-title":"Eur J Cancer"},{"key":"BFbmt200869_CR28","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1016\/0959-8049(92)90509-Z","volume":"28A","author":"R Corbett","year":"1992","unstructured":"Corbett R, Pinkerton R, Pritchard J, Meller S, Lewis I, Kingston J et al. Pilot study of high-dose vincristine, etoposide, carboplatin and melphalan with autologous bone marrow rescue in advanced neuroblastoma. Eur J Cancer 1992; 28A: 1324\u20131328.","journal-title":"Eur J Cancer"},{"key":"BFbmt200869_CR29","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1200\/JCO.1996.14.9.2417","volume":"14","author":"DO Stram","year":"1996","unstructured":"Stram DO, Matthay KK, O'Leary M, Reynolds CP, Haase GM, Atkinson JB et al. Consolidation chemoradiotherapy and autologous bone marrow transplantation versus continued chemotherapy for metastatic neuroblastoma: a report of two concurrent Children's Cancer Group studies. J Clin Oncol 1996; 14: 2417\u20132426.","journal-title":"J Clin Oncol"},{"key":"BFbmt200869_CR30","first-page":"125","volume":"18","author":"A Garaventa","year":"1996","unstructured":"Garaventa A, Rondelli R, Lanino E, Dallorso S, Dini G, Bonetti F et al. Myeloablative therapy and bone marrow rescue in advanced neuroblastoma. Report from the Italian Bone Marrow Transplant Registry. Italian Association of Pediatric Hematology-Oncology, BMT Group. Bone Marrow Transplant 1996; 18: 125\u2013130.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt200869_CR31","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1002\/1097-0142(20001115)89:10<2122::AID-CNCR13>3.0.CO;2-K","volume":"89","author":"BH Kushner","year":"2000","unstructured":"Kushner BH, Heller G, Kramer K, Cheung NK . Granulocyte-colony stimulating factor and multiple cycles of strongly myelosuppressive alkylator-based combination chemotherapy in children with neuroblastoma. Cancer 2000; 89: 2122\u20132130.","journal-title":"Cancer"},{"key":"BFbmt200869_CR32","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1200\/JCO.1991.9.6.1037","volume":"9","author":"T Philip","year":"1991","unstructured":"Philip T, Zucker JM, Bernard JL, Lutz P, Bordigoni P, Plouvier E et al. Improved survival at 2 and 5 years in the LMCE1 unselected group of 72 children with stage IV neuroblastoma older than 1 year of age at diagnosis: is cure possible in a small subgroup? J Clin Oncol 1991; 9: 1037\u20131044.","journal-title":"J Clin Oncol"},{"key":"BFbmt200869_CR33","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1200\/JCO.1995.13.11.2789","volume":"13","author":"GB McCowage","year":"1995","unstructured":"McCowage GB, Vowels MR, Shaw PJ, Lockwood L, Mameghan H . Autologous bone marrow transplantation for advanced neuroblastoma using teniposide, doxorubicin, melphalan, cisplatin, and total-body irradiation. J Clin Oncol 1995; 13: 2789\u20132795.","journal-title":"J Clin Oncol"},{"key":"BFbmt200869_CR34","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1200\/JCO.1998.16.3.937","volume":"16","author":"MF Ozkaynak","year":"1998","unstructured":"Ozkaynak MF, Matthay K, Cairo M, Harris RE, Feig S, Reynolds CP et al. Double-alkylator non-total-body irradiation regimen with autologous hematopoietic stem-cell transplantation in pediatric solid tumors. J Clin Oncol 1998; 16: 937\u2013944.","journal-title":"J Clin Oncol"},{"key":"BFbmt200869_CR35","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s00066-006-1498-8","volume":"182","author":"T Simon","year":"2006","unstructured":"Simon T, Hero B, Bongartz R, Schmidt M, Muller RP, Berthold F . Intensified external-beam radiation therapy improves the outcome of stage 4 neuroblastoma in children &gt;1 year with residual local disease. Strahlenther Onkol 2006; 182: 389\u2013394.","journal-title":"Strahlenther Onkol"},{"key":"BFbmt200869_CR36","first-page":"228","volume":"35","author":"R Corbett","year":"1991","unstructured":"Corbett R, Pinkerton R, Tait D, Meller S . [131I]metaiodobenzylguanidine and high-dose chemotherapy with bone marrow rescue in advanced neuroblastoma. J Nucl Biol Med 1991; 35: 228\u2013231.","journal-title":"J Nucl Biol Med"},{"key":"BFbmt200869_CR37","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1016\/S0959-8049(98)00130-0","volume":"34","author":"T Klingebiel","year":"1998","unstructured":"Klingebiel T, Bader P, Bares R, Beck J, Hero B, Jurgens H et al. Treatment of neuroblastoma stage 4 with 131I-meta-iodo-benzylguanidine, high-dose chemotherapy and immunotherapy. A pilot study. Eur J Cancer 1998; 34: 1398\u20131402.","journal-title":"Eur J Cancer"},{"key":"BFbmt200869_CR38","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1055\/s-0038-1625111","volume":"45","author":"M Schmidt","year":"2006","unstructured":"Schmidt M, Simon T, Hero B, Eschner W, Dietlein M, Sudbrock F et al. Is there a benefit of 131 I-MIBG therapy in the treatment of children with stage 4 neuroblastoma? A retrospective evaluation of The German Neuroblastoma Trial NB97 and implications for The German Neuroblastoma Trial NB2004. Nuklearmedizin 2006; 45: 145\u2013151; quiz N39\u2013N40.","journal-title":"Nuklearmedizin"},{"key":"BFbmt200869_CR39","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/0959-8049(94)E0036-4","volume":"31A","author":"MN Gaze","year":"1995","unstructured":"Gaze MN, Wheldon TE, O'Donoghue JA, Hilditch TE, McNee SG, Simpson E et al. Multi-modality megatherapy with [131I]meta-iodobenzylguanidine, high dose melphalan and total body irradiation with bone marrow rescue: feasibility study of a new strategy for advanced neuroblastoma. Eur J Cancer 1995; 31A: 252\u2013256.","journal-title":"Eur J Cancer"},{"key":"BFbmt200869_CR40","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1200\/JCO.1998.16.1.229","volume":"16","author":"KK Matthay","year":"1998","unstructured":"Matthay KK, DeSantes K, Hasegawa B, Huberty J, Hattner RS, Ablin A et al. Phase I dose escalation of 131I-metaiodobenzylguanidine with autologous bone marrow support in refractory neuroblastoma. J Clin Oncol 1998; 16: 229\u2013236.","journal-title":"J Clin Oncol"},{"key":"BFbmt200869_CR41","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1038\/sj.bmt.1702846","volume":"27","author":"M Miano","year":"2001","unstructured":"Miano M, Garaventa A, Pizzitola MR, Piccolo MS, Dallorso S, Villavecchia GP et al. Megatherapy combining I(131) metaiodobenzylguanidine and high-dose chemotherapy with haematopoietic progenitor cell rescue for neuroblastoma. Bone Marrow Transplant 2001; 27: 571\u2013574.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt200869_CR42","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1089\/cbr.2005.20.195","volume":"20","author":"MN Gaze","year":"2005","unstructured":"Gaze MN, Chang YC, Flux GD, Mairs RJ, Saran FH, Meller ST . Feasibility of dosimetry-based high-dose 131I-meta-iodobenzylguanidine with topotecan as a radiosensitizer in children with metastatic neuroblastoma. Cancer Biother Radiopharm 2005; 20: 195\u2013199.","journal-title":"Cancer Biother Radiopharm"},{"key":"BFbmt200869_CR43","first-page":"69","volume":"39","author":"S Mastrangelo","year":"1995","unstructured":"Mastrangelo S, Tornesello A, Diociaiuti L, Riccardi R, Rufini V, Troncone L . Treatment with meta-[131I]iodobenzylguanidine and cisplatin in stage IV neuroblastoma. Q J Nucl Med 1995; 39: 69\u201371.","journal-title":"Q J Nucl Med"},{"key":"BFbmt200869_CR44","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1054\/bjoc.2000.1645","volume":"84","author":"S Mastrangelo","year":"2001","unstructured":"Mastrangelo S, Tornesello A, Diociaiuti L, Pession A, Prete A, Rufini V et al. Treatment of advanced neuroblastoma: feasibility and therapeutic potential of a novel approach combining 131-I-MIBG and multiple drug chemotherapy. Br J Cancer 2001; 84: 460\u2013464.","journal-title":"Br J Cancer"},{"key":"BFbmt200869_CR45","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1200\/JCO.1987.5.8.1205","volume":"5","author":"O Hartmann","year":"1987","unstructured":"Hartmann O, Benhamou E, Beaujean F, Kalifa C, Lejars O, Patte C et al. Repeated high-dose chemotherapy followed by purged autologous bone marrow transplantation as consolidation therapy in metastatic neuroblastoma. J Clin Oncol 1987; 5: 1205\u20131211.","journal-title":"J Clin Oncol"},{"key":"BFbmt200869_CR46","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/bjc.1993.21","volume":"67","author":"T Philip","year":"1993","unstructured":"Philip T, Ladenstein R, Zucker JM, Pinkerton R, Bouffet E, Louis D et al. Double megatherapy and autologous bone marrow transplantation for advanced neuroblastoma: the LMCE2 study. Br J Cancer 1993; 67: 119\u2013127.","journal-title":"Br J Cancer"},{"key":"BFbmt200869_CR47","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.1200\/JCO.2006.05.6986","volume":"24","author":"RE George","year":"2006","unstructured":"George RE, Li S, Medeiros-Nancarrow C, Neuberg D, Marcus K, Shamberger RC et al. High-risk neuroblastoma treated with tandem autologous peripheral-blood stem cell-supported transplantation: long-term survival update. J Clin Oncol 2006; 24: 2891\u20132896.","journal-title":"J Clin Oncol"},{"key":"BFbmt200869_CR48","first-page":"37","volume":"14","author":"R Ladenstein","year":"1994","unstructured":"Ladenstein R, Lasset C, Hartmann O, Klingebiel T, Bouffet E, Gadner H et al. Comparison of auto versus allografting as consolidation of primary treatments in advanced neuroblastoma over one year of age at diagnosis: report from the European Group for Bone Marrow Transplantation. Bone Marrow Transplant 1994; 14: 37\u201346.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt200869_CR49","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1200\/JCO.1994.12.11.2382","volume":"12","author":"KK Matthay","year":"1994","unstructured":"Matthay KK, Seeger RC, Reynolds CP, Stram DO, O'Leary MC, Harris RE et al. Allogeneic versus autologous purged bone marrow transplantation for neuroblastoma: a report from the Childrens Cancer Group. J Clin Oncol 1994; 12: 2382\u20132389.","journal-title":"J Clin Oncol"},{"key":"BFbmt200869_CR50","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/sj.bmt.1704070","volume":"32","author":"M Inoue","year":"2003","unstructured":"Inoue M, Nakano T, Yoneda A, Nishikawa M, Nakayama M, Yumura-Yagi K et al. Graft-versus-tumor effect in a patient with advanced neuroblastoma who received HLA haplo-identical bone marrow transplantation. Bone Marrow Transplant 2003; 32: 103\u2013106.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt200869_CR51","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1080\/14653249910001591276","volume":"1","author":"A Verdeguer","year":"1999","unstructured":"Verdeguer A, Bermudez M, De La Rubia J, Fernandez J, Canete A, Castel V . Allogeneic PBPC transplantation in Children. Cytotherapy 1999; 1: 195\u2013201.","journal-title":"Cytotherapy"},{"key":"BFbmt200869_CR52","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1038\/sj.bmt.1705681","volume":"39","author":"A Marabelle","year":"2007","unstructured":"Marabelle A, Paillard C, Tchirkov A, Halle P, Chassagne J, Demeocq F et al. Graft-versus-tumour effect in refractory metastatic neuroblastoma. Bone Marrow Transplant 2007; 39: 809\u2013810.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt200869_CR53","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1055\/s-2006-942256","volume":"218","author":"P Lang","year":"2006","unstructured":"Lang P, Pfeiffer M, Muller I, Schumm M, Ebinger M, Koscielniak E et al. Haploidentical stem cell transplantation in patients with pediatric solid tumors: preliminary results of a pilot study and analysis of graft versus tumor effects. Klinische Padiatrie 2006; 218: 321\u2013326.","journal-title":"Klinische Padiatrie"},{"key":"BFbmt200869_CR54","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1097\/01.tp.0000225780.90991.49","volume":"82","author":"M Hirayama","year":"2006","unstructured":"Hirayama M, Azuma E, Araki M, Komada Y, Nakagawa A . Evidence of graft-versus-tumor effect in refractory metastatic neuroblastoma. Transplantation 2006; 82: 142\u2013144.","journal-title":"Transplantation"},{"key":"BFbmt200869_CR55","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1182\/blood.V77.8.1717.1717","volume":"77","author":"RJ Berenson","year":"1991","unstructured":"Berenson RJ, Bensinger WI, Hill RS, Andrews RG, Garcia-Lopez J, Kalamasz DF et al. Engraftment after infusion of CD34+ marrow cells in patients with breast cancer or neuroblastoma. Blood 1991; 77: 1717\u20131722.","journal-title":"Blood"},{"key":"BFbmt200869_CR56","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1111\/j.1365-2141.1994.tb06744.x","volume":"87","author":"WI Bensinger","year":"1994","unstructured":"Bensinger WI, Longin K, Appelbaum F, Rowley S, Weaver C, Lilleby K et al. Peripheral blood stem cells (PBSCs) collected after recombinant granulocyte colony stimulating factor (rhG-CSF): an analysis of factors correlating with the tempo of engraftment after transplantation. Br J Haematol 1994; 87: 825\u2013831.","journal-title":"Br J Haematol"},{"key":"BFbmt200869_CR57","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/j.1365-2141.1995.tb05344.x","volume":"91","author":"C Tarella","year":"1995","unstructured":"Tarella C, Benedetti G, Caracciolo D, Castellino C, Cherasco C, Bondesan P et al. Both early and committed haemopoietic progenitors are more frequent in peripheral blood than in bone marrow during mobilization induced by high-dose chemotherapy + G-CSF. Br J Haematol 1995; 91: 535\u2013543.","journal-title":"Br J Haematol"},{"key":"BFbmt200869_CR58","first-page":"487","volume":"29A","author":"A Garaventa","year":"1993","unstructured":"Garaventa A, Ladenstein R, Chauvin F, Lanino E, Philip I, Corciulo P et al. High-dose chemotherapy with autologous bone marrow rescue in advanced stage IV neuroblastoma. Eur J Cancer 1993; 29A: 487\u2013491.","journal-title":"Eur J Cancer"},{"key":"BFbmt200869_CR59","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1182\/blood.V84.2.380.380","volume":"84","author":"DR Rill","year":"1994","unstructured":"Rill DR, Santana VM, Roberts WM, Nilson T, Bowman LC, Krance RA et al. Direct demonstration that autologous bone marrow transplantation for solid tumors can return a multiplicity of tumorigenic cells. Blood 1994; 84: 380\u2013383.","journal-title":"Blood"},{"key":"BFbmt200869_CR60","doi-asserted-by":"crossref","first-page":"9505","DOI":"10.1200\/jco.2007.25.18_suppl.9505","volume":"25","author":"SG Kreissman","year":"2007","unstructured":"Kreissman SG, Villablanca JG, Diller L, London WB, Maris JM, Park JR et al. Response and toxicity to a dose-intensive multi-agent chemotherapy induction regimen for high risk neuroblastoma (HR-NB): a Children's Oncology Group (COG A3973) study. J Clin Oncol 2007; 2007 ASCO Annual Meeting Proceedings Part I 25(18S): 9505.","journal-title":"J Clin Oncol"},{"key":"BFbmt200869_CR61","doi-asserted-by":"crossref","first-page":"3423","DOI":"10.1200\/JCO.2005.03.9271","volume":"24","author":"JG Villablanca","year":"2006","unstructured":"Villablanca JG, Krailo MD, Ames MM, Reid JM, Reaman GH, Reynolds CP . Phase I trial of oral fenretinide in children with high-risk solid tumors: a report from the Children's Oncology Group (CCG 09709). J Clin Oncol 2006; 24: 3423\u20133430.","journal-title":"J Clin Oncol"},{"key":"BFbmt200869_CR62","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0304-3835(03)00108-3","volume":"197","author":"CP Reynolds","year":"2003","unstructured":"Reynolds CP, Matthay KK, Villablanca JG, Maurer BJ . Retinoid therapy of high-risk neuroblastoma. Cancer Lett 2003; 197: 185\u2013192.","journal-title":"Cancer Lett"},{"key":"BFbmt200869_CR63","first-page":"1445","volume":"23","author":"F Marti","year":"1995","unstructured":"Marti F, Pardo N, Peiro M, Bertran E, Amill B, Garcia J et al. Progression of natural immunity during one-year treatment of residual disease in neuroblastoma patients with high doses of interleukin-2 after autologous bone marrow transplantation. Exp Hematol 1995; 23: 1445\u20131452.","journal-title":"Exp Hematol"},{"key":"BFbmt200869_CR64","first-page":"293","volume":"385","author":"J Michon","year":"1994","unstructured":"Michon J, Negrier S, Coze C, Mathiot C, Frappaz D, Oskam R et al. Administration of high-dose recombinant interleukin 2 after autologous bone marrow transplantation in patients with neuroblastoma: toxicity, efficacy and survival. A Lyon-Marseille-Curie-east of France Group Study. Prog Clin Biol Res 1994; 385: 293\u2013300.","journal-title":"Prog Clin Biol Res"},{"key":"BFbmt200869_CR65","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1002\/(SICI)1096-911X(199612)27:6<534::AID-MPO5>3.0.CO;2-M","volume":"27","author":"N Pardo","year":"1996","unstructured":"Pardo N, Marti F, Fraga G, Illa J, Badell I, Peiro M et al. High-dose systemic interleukin-2 therapy in stage IV neuroblastoma for one year after autologous bone marrow transplantation: pilot study. Med Ped Oncol 1996; 27: 534\u2013539.","journal-title":"Med Ped Oncol"},{"key":"BFbmt200869_CR66","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1038\/bjc.1998.527","volume":"78","author":"A Pession","year":"1998","unstructured":"Pession A, Prete A, Locatelli F, Pierinelli S, Pession AL, Maccario R et al. Immunotherapy with low-dose recombinant interleukin 2 after high-dose chemotherapy and autologous stem cell transplantation in neuroblastoma. Br J Cancer 1998; 78: 528\u2013533.","journal-title":"Br J Cancer"},{"key":"BFbmt200869_CR67","first-page":"515","volume":"16","author":"D Valteau-Couanet","year":"1995","unstructured":"Valteau-Couanet D, Rubie H, Meresse V, Farace F, Brandely M, Hartmann O . Phase I-II study of interleukin-2 after high-dose chemotherapy and autologous bone marrow transplantation in poorly responding neuroblastoma. Bone Marrow Transplant 1995; 16: 515\u2013520.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt200869_CR68","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1158\/1078-0432.CCR-05-2000","volume":"12","author":"KL Osenga","year":"2006","unstructured":"Osenga KL, Hank JA, Albertini MR, Gan J, Sternberg AG, Eickhoff J et al. A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology Group. Clin Cancer Res 2006; 12: 1750\u20131759.","journal-title":"Clin Cancer Res"},{"key":"BFbmt200869_CR69","doi-asserted-by":"crossref","first-page":"3549","DOI":"10.1200\/JCO.2004.08.143","volume":"22","author":"T Simon","year":"2004","unstructured":"Simon T, Hero B, Faldum A, Handgretinger R, Schrappe M, Niethammer D et al. Consolidation treatment with chimeric anti-GD2-antibody ch14.18 in children older than 1 year with metastatic neuroblastoma. J Clin Oncol 2004; 22: 3549\u20133557.","journal-title":"J Clin Oncol"},{"key":"BFbmt200869_CR70","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1055\/s-2005-836518","volume":"217","author":"T Simon","year":"2005","unstructured":"Simon T, Hero B, Faldum A, Handgretinger R, Schrappe M, Niethammer D et al. Infants with stage 4 neuroblastoma: the impact of the chimeric anti-GD2-antibody ch14.18 consolidation therapy. Klinische Padiatrie 2005; 217: 147\u2013152.","journal-title":"Klinische Padiatrie"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/bmt200869.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt200869","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt200869.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T07:29:49Z","timestamp":1648020589000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bmt200869"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,6,1]]},"references-count":70,"journal-issue":{"issue":"S2","published-print":{"date-parts":[[2008,6,1]]}},"alternative-id":["BFbmt200869"],"URL":"https:\/\/doi.org\/10.1038\/bmt.2008.69","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,6,1]]},"assertion":[{"value":"11 June 2008","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}